



STOCKS DOWN UNDER

INVESTOR NEWSLETTER

Stock of the week: Centrex (ASX:CXM)

CXM exported an impressive 19kt of phosphate in 2Q23

It is still only early days for Centrex's (ASX:CXM) Ardmore phosphate project, but there are very positive signs out of the company. After selling a trivial amount in 1Q23, the company revealed that it sold a total of 19,675t of phosphate in its latest quarter. And prices are high. The best news is ... the market has not caught on to this beauty ... yet!



[Click here to read the full story](#)


Other Stocks Down Under Insights this week

This week we also wrote about AGL, Virgin Australia, what the best trading platform is for ASX shares, BluGlass, JB HiFi, HUB24, Data#3, tips to rebuild your wealth after divorce and who make better investors - men or women?



Virgin Australia

One of the market's worst-kept secrets has been confirmed – a Virgin Australia IPO is on. The AFR reports that private equity



BluGlass

BluGlass' (ASX:BLG) latest shareholder update should give its investors significant cause for optimism. The company's

firm Bain Capital, which bought a 95% stake in Virgin Australia when the airline went into administration in the early days of the COVID pandemic, is looking for advice on potential float structures and valuations. As it is with any Private Equity IPO, it will be a case of buyer beware – particularly a Virgin Australia IPO.

[Read the full story](#)

passed yet another major milestone en route to commercialisation. Specifically, the first lasers produced from its Fremont fab were meeting or exceeding performance benchmarks that BluGlass has set for its contract manufacturers. This will be good news for BLG' margins when production is brought in-house.

[Read the full story](#)

[READ ALL OF THIS WEEK'S NEWS HERE](#)

Investor Webinar 18 January 2023

Weebit Nano, Graphite and how to rebuild your wealth after divorce.




CHECK OUT ALL OUR VIDEOS HERE

Exclusive content for our Stocks Down Under subscribers



CBA

The Commonwealth Bank (ASX:CBA) is Australia's largest bank. It trades at a significant premium to its other Big Four peers with a market capitalisation of over \$170bn and a P/B multiple of nearly 2.4x (compared with the 1.7x sector average). You could argue that CBA deserves this premium, given that the bank has the most customers of the Big Four (over 15m customers), the largest market share in the home loans market (25%) and made the largest Return on Equity (ROE) of the Big Four two years running. But will this continue as interest rates rise?



Neuren Pharmaceuticals

There are very few Biotechs that more than doubled in the last year. Neuren Pharmaceuticals (ASX:NEU), however, is one of them. It's flagship asset Trofinetide has passed all clinical trial phases and is being examined by the FDA as a candidate drug to treat Rett Syndrome, a rare neurological disorder. A decision is due in the next couple of months and we think shareholders can be optimistic about the prospects of approval. We also think this approval may be just the beginning for NEU, considering it has other drugs in the clinic as well.

[Click here for the full story](#)



Charter Hall Long WALE REIT

Ever since its 2016 listing, Charter Hall Long WALE REIT (ASX: CLW) has been one of the ASX's most diversified and largest REITs. However, CLW has not been able to escape the impact from the dour property market, suffering a 12 month share price decline of 11%. This is in spite of the fact that its portfolio grew in the past year, something that can't be said in respect of many other REITs on the ASX. There are several reason why we like this REIT.

[Click here for the full story](#)

[Click here for the full story](#)



29Metals

When 29Metals (ASX:29M) first listed on the ASX in June 2021, it was the largest base metals IPO in more than a decade. There was arguably no better time for the company to list. Copper prices were at record highs, ensuring positive investor sentiment and a substantial cash flow buffer for the company's projects. While the first year of listed life went well for the company, the second year was very different, but copper is now picking up.

[Click here for the full story](#)



SiteMinder

We wrote about SiteMinder (ASX:SDR) roughly 12 months ago. The company has a SaaS platform that manages all of a hotel's needs to operate in the digital space, from guest data, reservations, UX design, web analytics and managing third-party hotel listings. It listed at the end of 2021 and initially rose on the hope that 2022 would be a rebound for travel and that the company could cash in. But during the 2022 Tech Crunch, investors have become increasingly deaf towards companies that are not profitable yet. We think this stock is four stars, though. Find out why!

[Click here for the full story](#)

Looking for BUY and SELL alerts on ASX-listed stocks?

Try Stocks Down Under CONCIERGE!

Concierge consistently outperforms the broader market!



- Trade alerts by SMS and email
- Buy ranges
- Target prices
- Stop Loss levels

Try out CONCIERGE for 3 months...for FREE

Did you know that you can read all our previous Investor Newsletters in our archive?

Go to Newsletter Archive now

